Schott Harold C, Strachota Julie R, Marteniuk Judith V, Refsal Kent R
Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan, USA.
Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
J Vet Intern Med. 2025 May-Jun;39(3):e70109. doi: 10.1111/jvim.70109.
Limited data document long-term responses of equids with pituitary pars intermedia dysfunction (PPID) to pergolide treatment.
Report clinical response, medical problems, outcome, and owner satisfaction with pergolide treatment of PPID-affected equids over 14 years.
Thirty client-owned equids with PPID.
After completion of an open field clinical efficacy study for Prascend® (pergolide tablets), 28 horses and two ponies were enrolled in an extended treatment study (13 receiving 2 μg/kg PO q24h and 17 receiving 4 μg/kg PO q24h). Clients were interviewed every 3 months and equids were re-evaluated after 2.5, 3, 3.5, 4.5, 5.5, 6.5, 9.5, 12.5, and 14.5 years of treatment.
Five equids died and 24 were euthanized (five for chronic laminitis) during the study period (median survival time, 3.6 years; range 0.6-10.5 years). Seven of 13 equids had a dosage increase to 4 μg/kg PO q24h (maximum study dose) between 1.7 to 4.7 years of the study. After 5.5 years, owners of 13 surviving equids reported sustained clinical improvement and endocrine test results normalized in 75%. After 9.5 years of treatment, only two of six surviving equids had normal endocrine test results.
Long-term treatment of PPID-affected equids with pergolide produces clinical improvement in nearly all affected animals and normalization of endocrine test results in some cases. Furthermore, this extended treatment study determined that equids can respond favorably long-term to the initial pergolide dose, rather than needing a progressive increase in dose over time.
关于患有垂体中间叶功能障碍（PPID）的马属动物对培高利特治疗的长期反应的数据有限。
报告14年间培高利特治疗患PPID马属动物的临床反应、医疗问题、结局及主人满意度。
30匹客户拥有的患PPID的马属动物。
在完成一项关于Prascend®（培高利特片）的旷场临床疗效研究后，28匹马和2匹矮种马被纳入一项延长治疗研究（13匹接受2μg/kg口服，每24小时一次；17匹接受4μg/kg口服，每24小时一次）。每3个月对客户进行访谈，并在治疗2.5、3、3.5、4.5、5.5、6.5、9.5、12.5和14.5年后对马属动物进行重新评估。
在研究期间，5匹马属动物死亡，24匹被安乐死（5匹因慢性蹄叶炎）（中位生存时间3.6年；范围0.6 - 10.5年）。13匹马属动物中有7匹在研究的1.7至4.7年期间剂量增加至4μg/kg口服，每24小时一次（研究最大剂量）。5.5年后，13匹存活马属动物的主人报告临床持续改善，75%的马属动物内分泌检测结果恢复正常。治疗9.5年后，6匹存活马属动物中只有2匹内分泌检测结果正常。
用培高利特长期治疗患PPID的马属动物，几乎所有患病动物的临床症状都有改善，部分病例内分泌检测结果恢复正常。此外，这项延长治疗研究确定，马属动物对初始培高利特剂量可长期产生良好反应，而非需要随时间逐渐增加剂量。
